In its three-decade journey, Japanese pharmaceutical giant Astellas has significantly enhanced patient access to innovative medicines in the Chinese mainland. By forging strong partnerships with local enterprises, the company has navigated the evolving pharmaceutical landscape to bring cutting-edge treatments to those in need.
In a recent discussion with CGTN's Wang Tianyu, Claus Zieler, Astellas' Chief Commercial Officer, delved into the state of pharmaceutical innovation and affordability in China. Zieler highlighted the strides made in medicine approval processes, enabling faster delivery of essential drugs to the market. He emphasized Astellas' commitment to affordability, ensuring that life-saving treatments remain accessible to a broader patient base.
Astellas continues to invest in research and development, collaborating with local companies to drive advancements in healthcare. This strategic approach not only supports the company's growth in the Chinese mainland but also contributes to the global effort in combating diseases and improving patient outcomes.
Reference(s):
cgtn.com
